Stability of tirofiban hydrochloride in three commonly used i.v. solutions and polyvinyl chloride administration sets

American Journal of Health-System Pharmacy

Volumn 56, Issue 16, 1999, Pages 1627-1629

  Bergquist, Paul A ^a   Zimmerman, Jeffery ^b   Kenney, Robert R ^b   Han, Ron Yieng Hau ^b   Hunke, William A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck and Co Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

POLYVINYLCHLORIDE; TIROFIBAN;

ARTICLE; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MECHANISM; DRUG STABILITY; DRUG STORAGE; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033567305     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.16.1627     Document Type: Article

References (4)

1. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338:1488-97.
2. Aggrastat package insert. West Point, PA: Merck; 1998 Dec.
3. The United States pharmacopeia, 23rd rev., and The national formulary, 18th ed. Rockville, MD: United States Pharmacopeial Convention; 1994:483-4,1418.
4. Sweetana S, Akers J. Solubility principles and practices for parenteral drug dosage form development. J Pharm Sci Technol. 1996; 50:330-42.